Company: SXTPW
Filing Date: 2025-07-07
Form Type: S-1
Source: 0001213900-25-061842
Chunk: 32

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-07
Form: S-1
Chunk 32
---
 anticipate that we will require additional capital to continue
as a going concern and expand our operations in accordance with our current business plan.

Suppliers

We have quality and contract manufacturing agreements
relating to Arakoda in place with Piramal Enterprises Limited (API, tablets) and PCI Pharma Services (secondary packaging) (“PCI”)
and supply/quality/pharmacovigilance agreements in place with Biocelect Pty Ltd, Scandinavian Biopharma, and Knight Therapeutics Inc.
(to allow supply of Arakoda/Kodatef to Australia, Europe and Canada/Israel/Latin America and Russia, respectively). As of the date of
this prospectus, we have not supplied any of our products to Russia nor do we anticipate supplying any of our products to Russia in the
near future.

Recent Developments

New FSU Option Agreement

On April 4, 2025, we entered into an option agreement
(the “Option Agreement”) with FSURF, the owner of certain patent rights and other patent and technology rights (“Patent
and Technology Rights”) relating to large scale purification of castanospermine.

Pursuant to the Option Agreement, FSURF granted
us an exclusive, limited-term option to negotiate a royalty-bearing, exclusive license to such Patent and Technology Rights within defined
fields of use (the “Option Rights”).

The option period commenced on April 4, 2025,
and will continue for twelve months (the “Option Period”), unless terminated earlier upon execution of a license agreement
or pursuant to the termination provisions in the Option Agreement. During the Option Period, the Company may use Patent and Technology
Rights solely for evaluation purposes.

The Option Agreement also includes certain provisions
relating to indemnification and termination rights. The Option Agreement and the Option Rights shall not be assignable, whether by operation
of law or otherwise, and any attempt to do so shall be void.

Castanospermine is a bioactive alkaloid derived
from the Australian Chestnut tree (Castanospermum australe). The Company has a long-standing intellectual property position around
the development of a synthetic castanospermine derivative, celgosivir, for viral diseases. Moreover, extensive scientific literature suggests
short-course botanically-derived castanospermine regimens may potentially beneficial metabolic and immunomodulatory effects. The development
and commercialization route for botanical extracts is far more efficient and less costly than for prescription pharmaceuticals.

<div align='center'>12</div>

Registered Direct Offer